Lisata Therapeutics (LSTA): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
3 concentrated managers hold it (+3 vs last quarter) with a median weight of 0.0%.
Who owns Lisata Therapeutics?
Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): Branham Justin Earl, 5.1% (13G filed Aug 26, 2026). As of Sep 30, 2026, the largest holders reported on Form 13F were Adage Capital Partners Gp, L.l.c (27.6% of the shares), Trv Gp V (5.1%) and Seven Fleet Capital Management (4.1%).
Which institutions hold the most Lisata Therapeutics shares?
Per Form 13F filings as of Sep 30, 2026, as a share of all shares outstanding:
- 1. Adage Capital Partners Gp, L.l.c: 27.6%
- 2. Trv Gp V: 5.1%
- 3. Seven Fleet Capital Management: 4.1%
- 4. Iii Services B.v Fcpm: 3.3%
- 5. Vanguard Capital Management: 3.1%
- 6. Alpha Wave Global: 2.0%
- 7. Sofinnova Investments: 1.7%
- 8. venBio Partners: 1.7%
- 9. Yakira Capital Management: 1.5%
- 10. Nantahala Capital Management: 1.1%
How much of Lisata Therapeutics do institutions own?
The 39 institutions that file 13F reported 58.2% of the shares as of Sep 30, 2026 (not counting 2 positions with implausible figures).
Sources:13G by Branham Justin Earl (Aug 26, 2026) ↗All of the company's proxy statements on EDGAR ↗
13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (Aug 6, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Lisata Therapeutics revenue
Lisata Therapeutics reported annual revenue of $170,000 for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).
Quarter flow (concentrated managers)
Change in managers (0 → 3): 3 opened · 0 exited = +3
Net flow in the quarter: +$918K (+637 K shares) · bought $918K and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
Concentrated managers holding it
- Iii Services B.V FcpmNew$428K0.0%+0.0 pp
- Alpha Wave GlobalNew$264K0.0%+0.0 pp
- Sofinnova InvestmentsNew$225K0.0%+0.0 pp
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders of LSTA (all 13F filers)
- Adage Capital Partners Gp, L.l.c2.5 MInvestment firm · 23.03% of the company+2.5 M
- TRV Gp V455 KType not verified · 4.21% of the company+455 K
- Seven Fleet Capital Management371 KType not verified · 3.44% of the company+371 K
- Iii Services B.v Fcpmconcentrated297 KType not verified · 2.75% of the company+297 K
- Vanguard Capital Management279 KIndex manager · 2.58% of the company0
- Alpha Wave Globalconcentrated183 KInvestment firm · 1.70% of the company+183 K
- Sofinnova Investmentsconcentrated156 KInvestment firm · 1.45% of the company+156 K
- venBio Partners156 KPrivate equity or venture capital · 1.45% of the company+156 K
- Yakira Capital Management136 KType not verified · 1.25% of the company−3,041
- Nantahala Capital Management101 KType not verified · 0.94% of the company+101 K
- Shares
- 2.5 M
- Change
- +2.5 M
- % of the company
- 23.03%
See more
- Type
- Investment firm
- Value
- $3.6M
- TRV Gp V
- Shares
- 455 K
- Change
- +455 K
- % of the company
- 4.21%
See more
- Type
- Type not verified
- Value
- $655K
- Seven Fleet Capital Management
- Shares
- 371 K
- Change
- +371 K
- % of the company
- 3.44%
See more
- Type
- Type not verified
- Value
- $535K
- Iii Services B.v Fcpmconcentrated
- Shares
- 297 K
- Change
- +297 K
- % of the company
- 2.75%
See more
- Type
- Type not verified
- Value
- $428K
- Shares
- 279 K
- Change
- 0
- % of the company
- 2.58%
See more
- Type
- Index manager
- Value
- $402K
- Alpha Wave Globalconcentrated
- Shares
- 183 K
- Change
- +183 K
- % of the company
- 1.70%
See more
- Type
- Investment firm
- Value
- $264K
- Sofinnova Investmentsconcentrated
- Shares
- 156 K
- Change
- +156 K
- % of the company
- 1.45%
See more
- Type
- Investment firm
- Value
- $225K
- Shares
- 156 K
- Change
- +156 K
- % of the company
- 1.45%
See more
- Type
- Private equity or venture capital
- Value
- $225K
- Yakira Capital Management
- Shares
- 136 K
- Change
- −3,041
- % of the company
- 1.25%
See more
- Type
- Type not verified
- Value
- $195K
- Shares
- 101 K
- Change
- +101 K
- % of the company
- 0.94%
See more
- Type
- Type not verified
- Value
- $146K
The 10 13F filers with the most shares as of Sep 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Held by institutions (13F)
Institutions (13F): 58.2% of the shares · top 10: 51.3% · in index firms: 9.5% of the institutional total
Q3 2026: 58.2%
Shares reported by the 39 13F filers as of Sep 30, 2026 (not counting 2 positions with implausible figures), divided by the shares outstanding on the cover of the company's latest report (Aug 6, 2026). It is not all institutional ownership: only managers with $100M or more file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.
Fundamentals
12-month figures to Sep 30, 2026 · balance sheet as of Sep 30, 2026.
- Operating margin
- —
- Net margin
- —
- ROE
- -224.5%
- Revenue (TTM)
- $100K
- Revenue growth
- -90.7%
- Net income (TTM)
- $-17.2M
- Net debt / EBITDA
- —
- Free cash flow (TTM)
- $-21.7M
- Quality vs sector
- —
This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.
Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated
Shares outstanding: buybacks and dilution
2025: 8.7 M
There is a jump that may be an undetected split: we do not show the changes.
- Buybacks (FY 2025)
- no data
- Share issuance
- $844K
- Stock-based compensation
- $1.2M721.2% of revenue
- Dividends paid
- no data
From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.
Earnings quality and debt
- Operating cash flow ÷ net income (12 months)
- no datanot calculated with negative net income
- Debt due within 12 months
- no data
From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.
Insiders (Form 4)
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
- Branham Justin Earl5.1%13Gfiling ↗Event: Aug 21, 2026 · filed: Aug 26, 2026
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
Flagged material events (8-K)
Exit or restructuring costs (Item 2.05)
Change in directors or officers (Item 5.02)
Change in directors or officers (Item 5.02)
«Lisata Therapeutics Appoints Jeff Farrow to Board of Directors»
Unregistered sale of equity securities (Item 3.02)
«Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement»
Change in directors or officers (Item 5.02)
«Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement»
Change in directors or officers (Item 5.02)
Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.
All material events (8-K)
Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Artiva BiotherapeuticsARTV · 4 managers
- AlumisALMS · 5 managers
- DavitaDVA · 5 managers
- KardiganKARD · 5 managers
- Sionna TherapeuticsSION · 5 managers
- Kodiak SciencesKOD · 6 managers